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Abstract Targeted toxins represent a new approach to specific
cytocidal therapy. The ribonucleolytic protein toxin restrictocin
is a potent protein synthesis inhibitor produced by the fungus
Aspergillus restrictus. In the present study we have constructed
two restrictocin based chimeric toxins where human transforming
growth factor alpha (TGFK) has been used as a ligand. TGFK is
a single chain polypeptide, which binds to epidermal growth
factor receptor (EGFR) and causes proliferation in a large
number of cancers. The ligand has been separately fused either at
the amino terminus or carboxyl terminus of restrictocin, giving
rise to TGFK-restrictocin and restrictocin-TGFK respectively.
The fusion proteins were overexpressed in Escherichia coli and
purified from inclusion bodies by a denaturation-renaturation
protocol. Both the chimeric toxins actively inhibited eukaryotic
protein synthesis in a cell free in vitro translation assay system.
These chimeric toxins selectively killed human epidermal growth
factor receptor positive target cells in culture. Among the two
proteins, restrictocin-TGFK was more active than TGFK-
restrictocin on all the cell lines studied.
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1. Introduction
One approach to cancer treatment that has received consid-
erable attention in the past few years is to direct protein
toxins to cancer cells [1,2]. Toxins have been genetically fused
to antibodies and growth factors to generate recombinant
immunotoxins or chimeric toxins that can selectively kill cells
bearing speci¢c receptors or antigens [1,2]. The potent inhib-
itory activity of bacterial toxins like Pseudomonas exotoxin
(PE) and diphtheria toxin (DT) as well as the plant toxin ricin
has been exploited for making chimeric toxins [1^4]. The
choice of both the toxin and the target is extremely important
in the construction of immunotoxins. An ideal target is either
unique to the malignancy or is present in a large excess on the
diseased cells to be eliminated [1]. Chimeric toxins have been
made using a variety of ligands such as transforming growth
factor alpha (TGFK), interleukin 2, interleukin 4, CD4, and
single chain antibodies [1,2,4]. TGFK is a mitogenic polypep-
tide of 50 amino acids and has structure and biological prop-
erties similar to that of epidermal growth factor (EGF) [5].
Both TGFK and EGF bind to subdomain III of the extrac-
ellular portion of epidermal growth factor receptor (EGFR),
causing receptor autophosphorylation and initiation of a cas-
cade of biochemical reactions that ultimately leads to DNA
synthesis and cell division [6,7]. Elevated expression of EGFR
is a characteristic of several malignancies including those of
breast, bladder, prostate, lung, cervical, thyroid, esophageal
and ovarian origin [8]. The EGF receptor contains a speci¢c
internalization sequence which contributes to the rapid inter-
nalization of the ligand receptor complex. Overexpression on
various cancers and rapid internalization of the EGFR makes
this receptor a good target for the selective delivery of anti-
cancer agents [8]. The factors that in£uence the potency of
immunotoxins in cancer therapy are their speci¢city, cytotox-
icity, tumor penetration, toxicity and immunogenicity [1,4].
Though highly potent and speci¢c immunotoxins have been
made, the toxicity and immunogenicity of these molecules has
limited their application [2]. Studies are now focused on en-
gineering the molecules further to resolve these issues. In ad-
dition, it would be helpful if new toxin molecules with low
non-speci¢c toxicity and immunogenicity are discovered, that
can be used in the construction of chimeric toxins [1,2].
Ribotoxins are ribosome inactivating proteins produced by
Aspergillus, that cleave a single phosphodiester bond on the 3P
side of G4325 in eukaryotic 28S rRNA [9]. The cleavage site is
embedded in a purine rich single stranded segment of 14 nu-
cleotides called the sarcin/ricin loop, which is one of the most
strongly conserved regions of rRNA. Cleaved 28S rRNA is
unable to participate in EF-1 dependent binding of aminoacyl
tRNA and EF-2 catalyzed GTP hydrolysis and translocation
during protein synthesis, leading to cell death [10]. Restricto-
cin, one of the members of the ribotoxin family, is a 149
amino acid single chain non-glycosylated polypeptide and a
potent inhibitor of translation [11]. Restrictocin cannot enter
into a cell on its own, and needs to be introduced inside the
cell by arti¢cial means to manifest its e¡ect. The killing po-
tency and absence of cell binding activity make restrictocin a
suitable molecule to be used as a toxin moiety of an immu-
notoxin [12^14]. Previously we have expressed restrictocin in
E. coli and shown that the recombinant toxin is as active as
the native protein [15]. We have also shown that recombinant
restrictocin has low toxicity, and is poorly immunogenic when
tested in mice [14]. We have earlier made active chemical
conjugates with recombinant restrictocin targeted at the hu-
man transferrin receptor [14]. Here we report on the construc-
tion and characterization of TGFK-based chimeric toxins of
restrictocin targeted at the human epidermal growth factor
receptor.
2. Materials and methods
2.1. Cell lines and cell culture
A431 (epidermoid carcinoma), A549 (lung carcinoma), K562 (er-
ythroleukemia) (all human) and L929, a mouse ¢broblast cell line,
were obtained from ATCC. All the cell lines were maintained in ex-
ponential growth in RPMI 1640 medium supplemented with 2 mM
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glutamine and 10% fetal calf serum, at 37³C in a humidi¢ed atmo-
sphere containing 5% CO
2
.
2.2. Construction of plasmids
To construct pTGFK-restrictocin, plasmid pVC320, containing
TGFK as a NdeI-NdeI insert, was digested with NdeI [16]. The puri-
¢ed insert was ligated into NdeI digested pRest, a T7 promoter based
bacterial expression vector, that contains restrictocin as an NdeI-
EcoRI fragment. The clone so generated contained DNA coding for
TGFK at the 5P end of restrictocin DNA. To construct pRestrictocin-
TGFK, restrictocin DNA was ampli¢ed by PCR from the plasmid
pRest to create NdeI sites at both the ends of the fragment [15].
PCR was used to create NdeI and EcoRI recognition sites respectively
at the 5P and 3P ends of the TGFK fragment, using pVC320 [16] as
template. Ampli¢ed fragment of restrictocin was digested with NdeI
while TGFK fragment was digested with NdeI and EcoRI. Both the
fragments were ligated in E. coli expression vector pVex11, digested
with NdeI and EcoRI. This gave rise to pRestrictocin-TGFK, contain-
ing DNA coding for TGFK at the 3P end of restrictocin. The correct
clones were identi¢ed by restriction analysis and protein expression.
E. coli strain DH5K was used for DNA manipulation.
2.3. Expression and puri¢cation of chimeric toxins
E. coli strain BL21 (VDE3) was used for protein expression. Cells
were separately transformed with pTGFK-restrictocin or pRestricto-
cin-TGFK and grown in super broth containing 100 Wg/ml of ampi-
cillin at 37³C with shaking. At an OD
600
of 2.0, the cells were induced
with 1 mM IPTG, and 2 h later, they were harvested by centrifugation
at 6000 rpm for 20 min. Inclusion bodies, isolated from the total cell
pellet using the protocol described [17], were denatured in guanidine
hydrochloride and reduced by dithioerythritol, followed by renatura-
tion in refolding bu¡er containing arginine and oxidized glutathione.
Renatured material was dialyzed against 50 mM phosphate bu¡er
(PB), pH 6.5, containing 100 mM urea and puri¢ed on a S-Sepharose
column using an FPLC system (Pharmacia). The fusion proteins were
puri¢ed to homogeneity by gel ¢ltration chromatography on a TSK
3000 column (LKB).
2.4. Ribonucleolytic activity of chimeric toxins
The ribonucleolytic activity of fusion proteins was assayed, in vitro,
by measuring the inhibition of translation of endogenous globin
mRNA of rabbit reticulocyte lysate in the presence of toxins. Rabbit
reticulocyte lysate was prepared and the assay performed as described
[18]. Incorporation of [
3
H]leucine was measured as a function of toxin
concentration.
2.5. Cytotoxicity and speci¢city of chimeric toxins
Activity of fusion proteins was evaluated on human carcinomas by
assaying protein synthesis, in the absence and presence of various
concentrations of toxins. After 48 h of incubation, with the toxin,
adherent cells (A431, A549) were washed twice with leucine free
DMEM and pulsed for 2 h with 0.25 WCi of [
3
H]leucine. Suspension
cells (K562) were directly labeled with 0.5 WCi of [
3
H]leucine for 2 h.
The cells were harvested on a glass ¢ber ¢lter and counted using a
LKB L-plate counter.
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Fig. 1. Schematic representation of chimeric toxins. In pTGFK-restrictocin, DNA encoding TGFK has been fused at the 5P end of restrictocin
DNA, while in the case of pRestrictocin-TGFK, it has been fused at the 3P end of restrictocin DNA. Amino acids, as single letter codes, shown
in bold uppercase letters are of restrictocin, while those shown in outlined uppercase represent amino acids of TGFK. Extra amino acids intro-
duced in the protein, because of the cloning strategy, are mentioned in lowercase letters. ORI: Bacterial origin of replication; F+: Bacterio-
phage origin of replication; AMP: ampicillin resistance gene; T7: T7 promoter.
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2.6. Binding assay
The binding of fusion proteins to EGF receptor was evaluated by
estimating their ability to displace iodinated epidermal growth factor
bound to A431 cells. EGF was iodinated using iodogen method [19].
In a 24 well plate, 40 000 cells were plated per well and left overnight
at 37³C to adhere. Cells were washed twice with binding bu¡er
(RPMI 1640 containing 2 mM glutamine, 25 mM HEPES pH 7.2
and 0.1% BSA) and used for the assay.
3. Results
3.1. Construction and expression of chimeric toxins
Plasmids pTGFK-restrictocin and pRestrictocin-TGFK are
T7 promoter based bacterial expression vectors, containing
DNA encoding TGFK cloned respectively at the 5P and 3P
end of restrictocin DNA. Fig. 1 shows the schematic repre-
sentations of these constructs. The constructs were separately
expressed in E. coli strain BL21 (VDE3), and in both cases, a
protein of the expected molecular weight (22 kDa) was over-
expressed as seen in the total cell pellet (Fig. 2, lane 1). Both
the fusion proteins accumulated in spheroplast, in the form of
insoluble inclusion bodies (Fig. 2, lane 2). The proteins were
puri¢ed from the inclusion bodies by a three step puri¢cation
protocol. In the ¢rst step, recombinant protein was isolated by
denaturation of puri¢ed inclusion bodies and renatured in
vitro. After renaturation, in the second step, chimeric toxins
were puri¢ed on a cation exchange column (Fig. 2, lane 3).
Proteins at this stage were almost 90% pure. In the last step,
protein from the cation exchange column was further puri¢ed
on a gel ¢ltration column to separate aggregated multimers of
the fusion proteins from the monomeric units (Fig. 2, lane 4).
For all subsequent studies, monomeric protein obtained from
the gel ¢ltration column was used.
3.2. In vitro activity of chimeric toxins
Earlier we have shown that recombinant restrictocin po-
tently inhibits protein synthesis in a rabbit reticulocyte based
cell free translation assay system [15]. TGFK-containing chi-
meric toxins were also evaluated in vitro, for their translation
inhibition activity. As shown in Fig. 3, both proteins e¡ec-
tively inhibited translation of endogenous globin mRNA in
the assay. Inhibition was dose dependent and the amount of
protein required to decrease protein synthesis to half (ID
50
)
was 0.15 and 0.40 nM for TGFK-restrictocin and restrictocin-
TGFK respectively. TGFK-restrictocin and restrictocin-TGFK
were respectively six-fold and 16-fold less active than recombi-
nant restrictocin, which had an ID
50
of 0.025 nM in the same
assay (Fig. 3).
3.3. Cytotoxicity and speci¢city of chimeric toxins
The cytotoxic potential of the two fusion proteins was eval-
uated on two target cell lines A431 and A549. The fusion
proteins inhibited protein synthesis in target cells in a dose
dependent manner (Fig. 4). Both restrictocin-TGFK and
TGFK-restrictocin showed maximum activity on A431 cells,
which express EGF receptor in excess, with ID
50
s of 1.66 nM
and 4.16 nM respectively. Restrictocin-TGFK was found to be
2.5-fold more active than TGFK-restrictocin (Table 1). On
A549, a human lung carcinoma, restrictocin-TGFK showed
activity similar to that on A431 but TGFK-restrictocin was
found to have no cytotoxicity. On a EGFR negative cell line
K562, both TGFK-restrictocin and restrictocin-TGFK were
inactive. To check whether these chimeric toxins also recog-
nize EGFR across the species, cytotoxic e¡ect of these toxins
was evaluated on a mouse ¢broblast cell line L929. Both pro-
teins had no cytotoxic e¡ect on a murine cell line L929, as no
inhibition of protein synthesis was observed even at a concen-
tration of 200 nM, indicating the speci¢c binding of the pro-
teins to the human EGF receptor (Table 1). Restrictocin alone
did not show any activity up to 115 nM (data not shown).
Speci¢city of the chimeric toxins for the EGFR was checked
by measuring their cytotoxic activity in the presence of free
EGF. Excess of free EGF (1 WM) prevented the cytotoxic
e¡ect of fusion toxins (Fig. 4).
3.4. Binding of chimeric toxins
As TGFK-restrictocin and restrictocin-TGFK showed di¡er-
ential activity on target cell lines, their binding activities to
EGF receptor were checked by measuring the ability of the
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Fig. 3. Activity of chimeric toxins in cell free translation assay sys-
tem. Rabbit reticulocyte lysate was incubated with di¡erent concen-
trations of TGFK-restrictocin (b), restrictocin-TGFK (F), and re-
strictocin (a), for 1 h at 30³C, and proteins were precipitated with
20% TCA. Precipitated material was collected on a glass ¢ber ¢lter
and counted on a beta counter for [
3
H]leucine incorporation. The
concentration of toxin required to inhibit protein synthesis by 50%
(ID
50
) was calculated by comparison with uninhibited protein sam-
ples.
Fig. 2. Puri¢cation of chimeric toxins. A and B represent TGFK-re-
strictocin and restrictocin-TGFK respectively. A 12% reducing SDS-
polyacrylamide gel was run and stained with Coomassie blue. Lane
1, total cell pellet; lane 2, inclusion bodies; lane 3, protein after S-
Sepharose column; lane 4, protein after gel ¢ltration. Molecular
weight markers are shown U10
33
Da.
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two fusion proteins to compete with [
125
I]EGF for binding to
the EGFR. As shown in Fig. 5, both proteins were found to
be equally potent in their ability to bind to the EGF receptor.
However, their binding activity was 50-fold lower than that of
the EGF.
4. Discussion
EGFR has been used as a target in the past with PE and
DT based chimeric toxins [8,16,20]. TGFK-PE40, a fusion
protein in which TGFK is fused at the amino terminus of a
truncated form of PE, has undergone clinical trials for the
intravesical therapy of bladder cancer [21]. DAB
389
EGF,
which contains EGF fused at the carboxyl terminus of a trun-
cated form of DT, has shown potent cytotoxic activity on
various target cell lines [8]. These studies show that a cyto-
toxic agent which targets the EGF receptor can be highly
selective and e¡ective for the treatment of carcinomas, char-
acterized by elevated EGF receptor expression. Previously we
have demonstrated that recombinant restrictocin is poorly im-
munogenic and has low in vivo toxicity in mice [14]. It has
also been used as a toxin component in the construction of
immunotoxin [14]. In the present study we have explored the
possibility of using restrictocin to construct chimeric toxin
using TGFK as ligand. In the two fusion proteins made, the
site of attachment of the ligand with respect to the toxin is
di¡erent. TGFK-restrictocin and restrictocin-TGFK contain
TGFK respectively at the amino and carboxyl ends of restric-
tocin. The constructs were expressed in E. coli and the pro-
teins were puri¢ed to homogeneity. Although TGFK-restric-
tocin had 2-fold higher in vitro ribonucleolytic activity than
restrictocin-TGFK, and they both bound to the EGFR with
equal a¤nities, yet on target cells restrictocin-TGFK was
found to be more toxic compared to TGFK-restrictocin. It
clearly indicates that the preferred site of ligand attachment
on restrictocin is at its carboxyl terminus. The site of attach-
ment of the ligand in a chimeric toxin critically in£uences its
cytotoxic potential. In DT based chimeric toxins, molecules
where the ligand is attached at the carboxyl terminus are
invariably more active than molecules where the ligand is
present at the amino terminus [1]. In the case of PE, the ligand
is attached at the amino terminus of the toxin, as the carboxyl
terminus of the toxin contains an endoplasmic retention signal
sequence and cannot be blocked [1].
Both chimeric toxins did not retain the full enzymatic ac-
tivity of restrictocin or the binding activity of the ligand. This
could be due either to misfolding of one protein with respect
to the other or to a steric hindrance posed by the additional
protein. However, despite the reduction in enzymatic and
binding activities of its components, the fusion proteins man-
ifested potent and speci¢c cytotoxic activities on the target
cells.
The cytotoxic activity of an immunotoxin or chimeric toxin
involves its binding to the target, intracellular processing, and
translocation to the intracellular target [1]. All these steps are
critical. As both restrictocin based chimeric toxins, TGFK-
restrictocin and restrictocin-TGFK bind EGFR with similar
a¤nities, di¡erences in their cytotoxic activities appear to be
due to the di¡erential intracellular processing and/or trans-
location. In this context, location of the binding ligand on
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Fig. 4. Activity of chimeric toxins on A431 cell line. TGFK-restrictocin (circles) or restrictocin-TGFK (squares) was added to the cells in the ab-
sence (open symbols) or in the presence (closed symbols) of excess 1 WM EGF for 48 h at 37³C. [
3
H]Leucine incorporation was measured as
described. The results are calculated as percentage of total radioactivity incorporated in the cells incubated without chimeric toxin.
Table 1
Cytotoxic activity of TGFK-based chimeric toxins
Cell line Origin ID
50
(nM)
TGFK-Restrictocin Restrictocin-TGFK
A431 Epidermoid carcinoma 4.16 1.66
A549 Lung carcinoma s 40.00 1.87
K562 Erythroleukemia s 40.00 s 40.00
L929 Mouse ¢broblast s 200.00 s 200.00
A431 or A549 cells were seeded at a density of 5U10
3
cells per well in 96 well plates, 16 h before the addition of toxin. K562 was seeded in 80%
leucine free DMEM containing 18% RPMI 1640 and 2% serum, and used immediately. Toxin was diluted in Dulbecco's PBS containing 0.2%
human serum albumin. ID
50
is the amount of chimeric toxin required to decrease protein synthesis to 50% of control, where no toxin has been
added.
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restrictocin appears to be critical and a carboxyl terminal
fusion appears to be tolerated better.
In conclusion, we have demonstrated that it is possible to
make restrictocin-based chimeric toxins directed at the human
EGF receptor. Chimeric toxins containing ligand at the car-
boxyl terminus of restrictocin had better cytotoxic activity.
The molecules generated in the current study contain toxin
and ligand fused in tandem without any linkers. Modi¢cation
of these proteins by introducing a spacer between the two
components may improve the folding of the molecule, thereby
further improving their biological activities. As restrictocin
has already been shown to have low in vivo toxicity and
immunogenicity, it holds potential for being used as a toxin
moiety in targeted therapy in the future.
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Fig. 5. Binding activity of chimeric toxins.
125
I-labeled EGF, at a
concentration of 1.5 ng per well, was added with various concentra-
tions of TGFK-restrictocin (b), restrictocin-TGFK (F) and EGF (a)
on A431 cells, in 0.2 ml of binding bu¡er. Cells were incubated for
1 h at 4³C. At the end of incubation, cells were washed three times
with binding bu¡er, and lysed with 10 mM Tris-HCl containing
0.5% SDS and 1 mM EDTA. The bound ligand was counted in a
gamma counter (LKB).
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